Back to Results
First PageMeta Content
Medical statistics / Lixivaptan / Electrolyte disturbances / Organochlorides / Design of experiments / Hyponatremia / Clinical trial / Vasopressin receptor antagonist / Tolvaptan / Medicine / Health / Epidemiology


FDA Briefing Document for the Cardiovascular and Renal Drugs Advisory (CRDAC) Meeting Date: 13 September 2012
Add to Reading List

Open Document

File Size: 4,36 MB

Share Result on Facebook
UPDATE